Abstract
Psychosis develops in as many as 40% of patients with Parkinson's disease who are treated with dopaminergic agents. In the past, options to treat psychosis were limited to reducing the dose of Parkinson's medication or adding antipsychotic medications associated with extrapyramidal side effects. Both of these approaches increased motor disability. Research and accumulating clinical experience indicate that the newer atypical antipsychotics provide a safe and effective way to manage psychosis in this patient population. For patients with combined parkinsonism and dementia, cholinesterase inhibitors may provide another option for treating psychosis.
| Original language | English |
|---|---|
| Pages (from-to) | 42-45 |
| Number of pages | 4 |
| Journal | Annals of Long-Term Care |
| Volume | 13 |
| Issue number | 5 |
| State | Published - May 2005 |
| Externally published | Yes |